Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries
- First Posted Date
- 2017-03-15
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1600
- Registration Number
- NCT03080935
- Locations
- 🇧🇪
Centre Hospitalier Universitaire Brugmann, Brussels, Belgium
🇧🇪Algemeen Ziekenhuis Sint Lucas, Gent, Belgium
🇧🇪Imelda Ziekenhuis vzw, Bonheiden, Belgium
A Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands
Completed
- Conditions
- Arthritis, Psoriatic
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Amgen
- Target Recruit Count
- 200
- Registration Number
- NCT02875184
- Locations
- 🇳🇱
MC Leeuwarden, Leeuwarden, Friesland, Netherlands
🇳🇱Research Site, Venlo, Netherlands
🇳🇱Reumazorg ZWN, Goes, Zeeland, Netherlands
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension
Phase 3
Completed
- Conditions
- Dyslipidemia
- Interventions
- Biological: Evolocumab
- First Posted Date
- 2016-08-16
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 5035
- Registration Number
- NCT02867813
- Locations
- 🇺🇦
Research Site, Zaporizhzhya, Ukraine
A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis
Phase 1
Completed
- Conditions
- Chronic Kidney Disease, Secondary Hyperparathyroidism
- Interventions
- First Posted Date
- 2016-07-14
- Last Posted Date
- 2019-07-10
- Lead Sponsor
- Amgen
- Target Recruit Count
- 11
- Registration Number
- NCT02833857
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Compare Actions in Healthy Volunteer of 50 mg Etanercept Injection Using an Auto-injector Device and Manual Injection
Phase 1
Completed
- Conditions
- Healthy Men and Women
- Interventions
- Device: Auto-injector deviceOther: Etanercept (ENBREL®) via Manual injection
- First Posted Date
- 2016-06-15
- Last Posted Date
- 2016-06-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 36
- Registration Number
- NCT02799498
An Study of Patients With Ph- Chromosome-negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the US
Completed
- Conditions
- Relapsed/Refractory Acute Lymphoblastic Leukemia
- Interventions
- Other: Other
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 212
- Registration Number
- NCT02783651
- Locations
- 🇺🇸
Research Site, Seattle, Washington, United States
Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab
Phase 3
Completed
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- Biological: RituximabBiological: ABP 798
- First Posted Date
- 2016-04-21
- Last Posted Date
- 2022-09-10
- Lead Sponsor
- Amgen
- Target Recruit Count
- 256
- Registration Number
- NCT02747043
- Locations
- 🇺🇦
Research Site, Dnipropetrovsk, Ukraine
Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous Sumatriptan
- First Posted Date
- 2016-04-18
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 34
- Registration Number
- NCT02741310
- Locations
- 🇧🇪
Research Site, Leuven, Belgium
A Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology Practice
Completed
- Conditions
- Psoriasis
- Interventions
- Other: Patient questionnaire
- First Posted Date
- 2016-04-15
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Amgen
- Target Recruit Count
- 610
- Registration Number
- NCT02740218
- Locations
- 🇩🇪
Praxis Dr. Schmeel, Wesseling, Germany
🇩🇪Praxis Dr. Buttgereit, Wildau, Germany
🇩🇪Praxis Dr. Neisius, Stolberg, Germany
A Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac Disease
Phase 2
Completed
- Conditions
- Celiac Disease
- Interventions
- Biological: AMG 714Biological: PlaceboOther: Placebo Gluten ChallengeOther: Gluten Challenge
- First Posted Date
- 2015-12-22
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- Amgen
- Target Recruit Count
- 64
- Registration Number
- NCT02637141
- Locations
- 🇫🇮
CRST, Turku, Finland
🇫🇮Tampere University Hospital, Tampere, Finland
🇫🇮ODL, Oulu, Finland
© Copyright 2025. All Rights Reserved by MedPath